Three key hormones regulate male reproductive health through a feedback loop that helps pinpoint the underlying cause of low testosterone levels.
Imagine opening a set of laboratory results and seeing three different numbers. Total testosterone is flagged as low, luteinizing hormone is sitting right in the middle of the reference interval, and follicle-stimulating hormone is near the bottom. Looking at each biomarker as an isolated checklist item often leads to confusion. One marker seems low, while the other two appear normal on paper.
In clinical endocrinology, hormones are rarely interpreted in isolation. Testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) operate as parts of a tightly coordinated communication network. Reading these markers together provides clues about where a hormonal disruption originates. It helps distinguish whether the testes are struggling to produce testosterone or if the brain is failing to send the proper signal.
This guide breaks down the biological feedback loops between the brain and the testes. It introduces a structured framework for reading hormone patterns, highlights common testing pitfalls, and explains what these patterns mean in clinical practice.
This resource is designed for educational purposes only. It does not provide medical advice, diagnosis, or treatment protocols. Interpreting hormone levels requires a comprehensive evaluation by a qualified healthcare professional who can assess your full medical history, physical symptoms, and repeat laboratory testing.
Understanding male hormone patterns relies on a few fundamental clinical principles:
To understand hormone patterns, you must first understand the signaling chain that regulates male hormone production. The body maintains testosterone and sperm production through a continuous feedback loop between the brain and the testes. This network is called the hypothalamic-pituitary-gonadal (HPG) axis.
The process begins in the hypothalamus, a specialized region at the base of the brain. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in rhythmic pulses. These pulses travel a short distance to the anterior pituitary gland, which sits just below the hypothalamus.
When stimulated by GnRH, the pituitary gland produces and secretes two primary signaling hormones into the bloodstream. These hormones are luteinizing hormone and follicle-stimulating hormone, collectively known as gonadotropins. Although both hormones are released by the pituitary, they target different cells within the testes and perform distinct tasks.
Luteinizing hormone travels through the bloodstream until it binds to receptors on the Leydig cells in the testes. Leydig cells make up the primary endocrine tissue of the testicles. Their main responsibility is converting cholesterol into testosterone.
When LH binds to Leydig cells, it stimulates the enzymatic cascade that produces testosterone. As testosterone enters the bloodstream, it circulates throughout the body to support muscle mass, bone density, red blood cell production, mood, and sexual function.
Testosterone also provides direct feedback to the brain. When circulating testosterone reaches adequate levels, it signals the hypothalamus and pituitary to decrease the release of GnRH and LH. If testosterone levels fall, the brain senses the reduction and increases LH secretion to stimulate production. This negative feedback loop keeps hormone concentrations within a relatively stable range.
While LH directs testosterone production, follicle-stimulating hormone primarily supports reproductive function. FSH binds to Sertoli cells located within the seminiferous tubules of the testes. Sertoli cells act as nurse cells that nourish, protect, and regulate developing sperm cells during spermatogenesis.
In response to FSH stimulation, Sertoli cells facilitate sperm maturation. They also produce a protein hormone called inhibin B. Inhibin B circulates back to the pituitary gland to provide targeted negative feedback, specifically inhibiting the release of FSH without suppressing LH.
Because FSH and LH respond to different feedback signals, they do not always rise or fall together. An issue that impairs sperm production without damaging Leydig cells can cause FSH to rise while LH and testosterone remain unaffected.
Understanding these distinct pathways is central to mastering testosterone fundamentals and interpreting lab panels correctly.
A comprehensive hormonal evaluation looks beyond a single total testosterone number. Clinicians use a panel of interconnected biomarkers to assess androgen status, binding proteins, and pituitary signaling.
Total testosterone measures the cumulative amount of testosterone circulating in the bloodstream. This includes hormone that is tightly bound to proteins, loosely bound to proteins, and circulating freely.
Testosterone production follows a circadian rhythm, peaking in the early morning hours and declining toward the evening. Because of this natural fluctuation, clinical guidelines require total testosterone to be measured in the morning while fasting.
Sex hormone-binding globulin (SHBG) is a glycoprotein produced primarily by the liver. It binds tightly to testosterone and dihydrotestosterone, regulating how much hormone is available to enter tissues.
Approximately 40 to 60 percent of circulating testosterone is bound tightly to SHBG. Another 40 to 58 percent is bound loosely to albumin, a common blood protein. Only about 1 to 2 percent circulates unbound as free testosterone.
Conditions that alter SHBG production can dramatically change total testosterone readings without changing the amount of active hormone reaching target tissues. For example, obesity, insulin resistance, and hypothyroidism often lower SHBG levels. Conversely, aging, liver disease, and hyperthyroidism can raise SHBG concentrations.
Free testosterone refers to the small fraction of hormone that is completely unbound to proteins. Bioavailable testosterone includes free testosterone plus the portion loosely attached to albumin, which can easily dissociate and enter target cells.
When SHBG levels are abnormally high or low, relying on total testosterone alone can lead to misinterpretation. In men with low SHBG, total testosterone may appear low even when free testosterone is well within normal limits. In men with elevated SHBG, total testosterone might appear normal despite a meaningful deficiency in free testosterone. Clinicians often calculate free testosterone using total testosterone, SHBG, and albumin measurements.
Measuring LH reveals how hard the pituitary gland is working to stimulate the testes. Because LH is released in short, pulsatile bursts throughout the day, a single blood draw captures a snapshot in time.
In clinical evaluation, LH is never interpreted on its own. It is always assessed relative to the circulating level of testosterone.
FSH reflects pituitary drive toward testicular Sertoli cells and sperm development. In men evaluated for hypogonadism or reproductive concerns, FSH helps assess the health of the seminiferous tubules.
Elevated FSH indicates that Sertoli cell function or sperm production is impaired, prompting the pituitary to increase its signaling efforts. Low or suppressed FSH indicates a lack of central stimulation or strong negative feedback from external hormones.
Prolactin is a hormone produced by the anterior pituitary gland. While it plays a major role in lactation in women, elevated prolactin in men can disrupt the pulsatile release of GnRH from the hypothalamus.
Measuring prolactin is an essential step when investigating low testosterone accompanied by low gonadotropins. Significantly elevated prolactin levels can point toward a prolactin-secreting pituitary adenoma or medication side effects that suppress the entire HPG axis.
Learning how to evaluate these individual markers together is a core focus of hormone blood testing.
When clinical symptoms and repeated laboratory testing confirm low testosterone, the next step is determining where the breakdown occurs. Clinicians classify male hypogonadism into three broad categories based on the relationship between testosterone and gonadotropin levels.
Primary hypogonadism occurs when the testes cannot produce adequate testosterone despite receiving strong signals from the brain. The underlying defect resides within the testicular tissue itself.
In this condition, damage or dysfunction in the Leydig cells reduces testosterone synthesis. Because testosterone levels are low, the normal negative feedback signal to the brain is absent. The hypothalamus and pituitary respond by increasing the production of GnRH, LH, and FSH.
As a result, the classic laboratory pattern for primary hypogonadism is low total or free testosterone paired with elevated LH and FSH. This state is sometimes referred to as hypergonadotropic hypogonadism.
Causes of primary hypogonadism include:
Secondary hypogonadism occurs when the testes are structurally capable of producing testosterone, but the brain fails to signal them to do so. The disruption originates in either the hypothalamus or the anterior pituitary gland.
In secondary hypogonadism, the pituitary does not release enough LH and FSH to stimulate the Leydig and Sertoli cells. Consequently, testosterone production drops. When blood tests are performed, testosterone is low, but LH and FSH levels are also low or fall within standard reference intervals. This presentation is referred to as hypogonadotropic hypogonadism.
It is important to emphasize that a normal LH or FSH reading is clinically abnormal when testosterone is low. A healthy pituitary should respond to low testosterone by surging its gonadotropin output. When LH remains in the mid or lower range despite low testosterone, the pituitary response is inappropriately low.
Causes of secondary hypogonadism include:
Mixed hypogonadism occurs when defects exist at both the testicular level and the hypothalamic-pituitary level. This combined presentation is common in older men and individuals with chronic multi-system illnesses.
In mixed hypogonadism, the testes have a reduced capacity to manufacture testosterone, but the pituitary also fails to mount a fully robust gonadotropin response. Testosterone is consistently low, while LH and FSH may sit in the upper-normal range rather than rising to the high levels seen in pure primary testicular failure.
Because mixed presentations involve multiple contributing factors, clinicians must evaluate the whole patient rather than relying solely on rigid diagnostic categories.
Interpreting male hormone laboratory panels requires an orderly, systematic approach. Following a structured step-by-step process prevents premature conclusions and reduces diagnostic errors.
Before analyzing LH, FSH, or other downstream markers, you must verify that testosterone deficiency actually exists. A single out-of-range lab result does not constitute a diagnosis of hypogonadism.
Clinical guidelines from major endocrine societies emphasize two strict criteria:
Testosterone levels fluctuate based on acute stress, poor sleep, recent alcohol intake, and acute illness. Repeating the test on a separate morning ensures that the initial low reading was not a transient dip. Furthermore, if total testosterone is borderline, measuring SHBG and calculating free testosterone is essential to confirm true androgen deficiency.
Once low testosterone is confirmed, examine the LH concentration to identify the primary level of signaling:
After evaluating the testosterone-LH relationship, examine FSH to assess Sertoli cell function and reproductive potential.
FSH provides information that LH cannot supply:
Before assuming a hormone pattern represents permanent organ damage, clinicians look for reversible physiological factors that influence the HPG axis.
Metabolic health plays a massive role in hormone signaling. Adipose tissue contains the enzyme aromatase, which converts testosterone into estradiol. Elevated estradiol exerts negative feedback on the hypothalamus and pituitary, lowering LH output. Additionally, obesity and insulin resistance suppress hepatic SHBG production, driving down total testosterone levels.
Other common confounders include:
The specific hormone pattern directs the next diagnostic steps. A primary pattern usually prompts a testicular examination, genetic screening, or a review of past toxic exposures.
A secondary pattern often requires a broader systemic workup:
Reviewing structured testosterone and biomarker guides can help clarify how these diagnostic steps fit together.
To help understand how these rules apply in practice, let us examine six common clinical hormone patterns. These examples illustrate the diagnostic logic clinicians use during an evaluation.
This is the classic primary testicular hypogonadism pattern. The low circulating testosterone level has removed negative feedback inhibition at the hypothalamus and pituitary. In response, the pituitary secretes large amounts of LH and FSH into circulation.
However, because the testicular tissue is damaged or dysfunctional, the Leydig cells cannot produce adequate testosterone, and the Sertoli cells cannot maintain normal spermatogenesis. This pattern indicates that the underlying disruption is located entirely within the testes.
Further evaluation involves investigating potential causes of testicular failure, such as previous chemotherapy, physical trauma, severe infections, or genetic conditions like Klinefelter syndrome.
This pattern represents classic secondary hypogonadism. Even though circulating testosterone is low, the pituitary gland is not increasing its production of LH and FSH. The gonadotropins may register below the laboratory reference interval or sit quietly within the standard range.
Because the expected physiological response to low testosterone is a surge in LH, a normal LH value in this context is abnormal. It demonstrates that the hypothalamic-pituitary signaling mechanism is failing to sense or respond to the low androgen state.
This pattern calls for an investigation into central causes, including metabolic dysfunction, severe sleep apnea, medication-induced suppression, hyperprolactinemia, or structural pituitary lesions.
This pattern is frequently observed in men with obesity, type 2 diabetes, metabolic syndrome, or fatty liver disease. In this scenario, hepatic synthesis of SHBG is suppressed due to elevated circulating insulin and inflammatory cytokines.
Because there is less binding protein in the blood, total testosterone measures below the reference range. However, because the fraction of unbound, active hormone remains intact, free testosterone levels are preserved. The pituitary senses adequate androgen activity and maintains normal LH and FSH signaling.
Treating this pattern as true hypogonadism is a common clinical mistake. The appropriate clinical focus here is addressing underlying metabolic health, insulin resistance, and lifestyle factors to restore normal SHBG synthesis.
In this presentation, the endocrine function of the testes is operating normally, but reproductive function is impaired. The Leydig cells are responding appropriately to normal LH levels, maintaining adequate circulating testosterone.
However, damage or intrinsic dysfunction within the seminiferous tubules or Sertoli cells has reduced the production of inhibin B. Without adequate inhibin B feedback, the pituitary increases FSH secretion.
This pattern is common in men presenting with fertility challenges or abnormal semen parameters. It shows that normal testosterone production does not guarantee normal spermatogenesis. A comprehensive fertility workup, including semen analysis, is necessary to fully evaluate this pattern.
This pattern is characteristic of exogenous androgen use. When a person receives testosterone therapy, anabolic steroids, or related compounds, the circulating androgens provide potent negative feedback to the hypothalamus and pituitary.
The brain interprets these high androgen levels as a signal that the body has abundant testosterone. Consequently, it completely shuts down the endogenous production of GnRH, LH, and FSH.
Without LH and FSH stimulation, the testes cease endogenous testosterone synthesis and sperm production. Clinicians cannot use blood tests drawn during exogenous hormone therapy to determine a patient's baseline natural hormone function.
When total testosterone drops to profound depths alongside low gonadotropins, the likelihood of an organic central disruption increases. While mild secondary hypogonadism is frequently functional and linked to lifestyle or metabolic factors, severe suppression requires a thorough medical investigation.
Endocrine guidelines recommend advanced diagnostic testing when confirmed testosterone levels fall below 150 ng/dL in a secondary pattern. This workup typically includes checking prolactin levels, screening for iron overload, evaluating the adrenal and thyroid axes, and performing a contrast-enhanced MRI of the sella turcica to inspect the pituitary gland.
For deeper insights on clinical thresholds and diagnostic algorithms, explore our guides on low testosterone evaluation.
Laboratory numbers do not exist in a vacuum. A wide range of biological, behavioral, and technical variables can alter blood test results. Clinicians must account for these confounding factors before arriving at a final diagnosis.
In young and middle-aged men, testosterone levels follow a distinct diurnal variation. Levels reach their daily peak between 7:00 AM and 10:00 AM and steadily decline throughout the afternoon and evening.
Testing drawn in the late afternoon can read 20 to 40 percent lower than a morning draw, creating an illusion of deficiency. For this reason, professional guidelines require blood samples to be collected in the early morning while fasting. In older men, this circadian variation blunts somewhat, but morning collection remains the gold standard.
The HPG axis is sensitive to physical illness and systemic inflammation. An acute viral infection, minor surgery, dental procedure, or sudden emotional crisis can temporarily downregulate GnRH and LH secretion, causing a sharp, temporary drop in testosterone.
Testing hormone levels during or immediately following an acute illness frequently yields misleading results. A complete evaluation should wait until the patient has fully recovered and returned to baseline health for several weeks.
Sleep architecture directly affects endocrine health. The primary pulse of natural testosterone production occurs during deep, uninterrupted rapid eye movement (REM) sleep.
Restricting sleep to four or five hours a night for even a single week can cause measurable decreases in daytime testosterone. Furthermore, obstructive sleep apnea (OSA) causes nocturnal hypoxia and sleep fragmentation, which impairs pituitary LH release. Screening for and treating sleep apnea often leads to improvements in endogenous hormone levels.
Extreme dietary approaches can alter hormone patterns. Severe caloric restriction, rapid weight loss, and very low-fat diets can downregulate pituitary signaling, leading to functional secondary hypogonadism.
Conversely, significant sustained weight loss in men with obesity reduces aromatase activity and lowers insulin levels. This shift often leads to an increase in SHBG, a rise in total testosterone, and improved pituitary sensitivity over time.
Many prescription and over-the-counter drugs affect the HPG axis:
Understanding these external influences is a core part of evaluating testosterone replacement therapy research and natural recovery options.
When navigating hormone health, it is essential to distinguish established clinical guidelines from preliminary research and observational associations.
Major medical organizations, including the Endocrine Society, the American Urological Association (AUA), and the European Association of Urology (EAU), provide evidence-based guidelines for managing male hypogonadism.
There is strong consensus across international guidelines on several core principles:
While the core diagnostic framework is widely accepted, differences exist regarding specific laboratory cutoffs and secondary workup criteria:
Recognizing the distinction between established medical guidelines and emerging concepts helps keep expectations realistic and conversations with doctors productive.
Navigating hormone testing results is best done in collaboration with an endocrinologist, urologist, or knowledgeable primary care physician. Bringing clear, focused questions to your appointment can help ensure a thorough and accurate evaluation.
Here are constructive questions to guide your discussion:
You may want to revisit this guide whenever you receive updated blood test results, experience changes in your physical symptoms, or begin a new phase of clinical evaluation. Comparing new laboratory panels against this framework can help you track how your hormone signaling changes over time and prepare you for follow-up discussions with your doctor.
Understanding how testosterone, LH, and FSH interact transforms a confusing collection of numbers into a clear, logical map of your endocrine health.
Testostra explains testosterone biology, testing, symptoms, lifestyle factors and TRT with careful sourcing and clear clinical limits.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra
